PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50126F61020Two-way immunogenicity testing on existing — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 75A50122D00002. Recompete timing centers on the Oct 29, 2026 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma
Awarding office
Glaxosmithkline LLC
Recipient
Oct 29, 2026
PoP end
$493K
Obligated
$493K
Potential
541714
NAICS
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal
Contract number75A50126F61020
Also listed as75A50122D00002-75A50126F61020
AgencyBarda - Aspr / Daappo / Barda Dcma
Awarding officeBarda - Aspr / Daappo / Barda Dcma
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentGlaxosmithkline LLC
CAGE667E9
UEIFRHTPHMZMX47
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV75A50122D00002
Place of performanceDURHAM NC
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startMar 13, 2026
PoP end (current)Oct 29, 2026
Obligated$493K
Current value$493K
Potential value$493K

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN is a federal award for Barda - Aspr / Daappo / Barda Dcma held by Glaxosmithkline LLC. Estimated value $493K ($493K obligated). Current period of performance ends Oct 29, 2026. Place of performance: DURHAM NC.

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN

Recompete timing

Public
Expiring in 69 days

Current PoP ends Oct 29, 2026 (69 days remaining). Agencies typically plan 12–18 months ahead — at 2.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Glaxosmithkline LLC$3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies
Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%
Open full company profile

Related awards

Same parent · incumbent
75A50125F61019
FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E
$491K
Aug 30, 2026
15F06724F0001366
GSK TRAVEL VACCINES
$115K
Dec 31, 2026
15F06726F0000234
GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187
$105K
Dec 31, 2026
75A50124F61014
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …
$18.4M
Feb 21, 2027
75A50124F61013
THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …
$15.4M
Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75A50126F61020?

75A50126F61020 (Two-way immunogenicity testing on existing) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $493K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50126F61020?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50126F61020 to Glaxosmithkline LLC (potential $493K).

Who is the incumbent on 75A50126F61020?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Oct 29, 2026.

When does Glaxosmithkline LLC’s 75A50126F61020 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 29, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50126F61020